비만

A new analysis of clinical trials indicates that semaglutide, the active ingredient in Ozempic and Wegovy, helps older adults with obesity lose substantial weight and improve heart health markers. The findings come from data on participants aged 65 and above who received the once-weekly medication alongside lifestyle changes.

2026년 05월 11일 AI에 의해 보고됨 사실 확인됨

An international meta-analysis slated for presentation at the European Congress on Obesity (ECO 2026) in Istanbul, Turkey (May 12–15) suggests that people who increase their walking to roughly 8,500 steps a day during a weight-loss program and sustain similar levels afterward may be less likely to regain weight.

An Italian research team comparing standard BMI categories with dual-energy X-ray absorptiometry (DXA) body-fat measurements found that more than one-third of adults were placed in the wrong weight category, and that BMI slightly overestimated the combined prevalence of overweight and obesity in the sample.

2026년 04월 01일 AI에 의해 보고됨

The US Food and Drug Administration approved Foundayo, a new once-daily pill for obesity treatment, on Wednesday. Eli Lilly, the manufacturer, also produces the weight-loss injection Zepbound. The approval positions Foundayo as the second obesity pill cleared by the FDA.

New research shows that visceral fat around the waist increases heart failure risk more than BMI, even among those with normal weight. Inflammation mediates much of this link. The findings were presented at the American Heart Association's EPI|Lifestyle Scientific Sessions 2026 in Boston.

2026년 03월 17일 AI에 의해 보고됨

홍콩 정부 보고서에 따르면 학생의 약 94%가 매일 충분한 운동을 하지 않으며, 17.5%는 과체중이라고 합니다. 또한 과일과 채소 섭취량이 적고, 시력 건강이 좋지 않으며, 학생들의 오락용 스크린 시청 시간이 지나치게 긴 것으로 나타났습니다.